This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Defensin peptides have broad-spectrum antiviral activity through direct viral inactivation and immunomodulation, with potential as therapeutic adjuvants against viral infections including COVID-19.
Why it matters
Viral pandemics demand rapid therapeutic responses. Defensins, as natural immune components with broad antiviral activity, could supplement vaccines and antiviral drugs as adjuvant therapies.
The numbers in context
α, β, θ defensin classes; broad-spectrum antiviral; immunomodulatory and immunoenhancing; potential anti-COVID-19 adjuvant; innate and adaptive immunity stimulation
How the study worked
Review of literature on defensin peptide antiviral mechanisms, applications, and potential as anti-coronavirus therapeutic adjuvants.
Who was studied
Review of defensin peptide antiviral mechanisms and therapeutic potential across viral infections
What this study cannot tell us
Review article. Most antiviral defensin data is in vitro. Clinical evidence for defensin-based antiviral therapy is limited. The COVID-19 application is theoretical and not yet tested in trials.
Read the original research
Promising role of defensins peptides as therapeutics to combat against viral infection.
Microbial pathogenesis, 155, 104930
Citation
Solanki, Subhash Singh; Singh, Parul; Kashyap, Poonam; Sansi, Manish Singh; Ali, Syed Azmal. (2021). Promising role of defensins peptides as therapeutics to combat against viral infection.. Microbial pathogenesis, 155, 104930. https://doi.org/10.1016/j.micpath.2021.104930